Laura Ghisolfi, Ph.D.
About Laura Ghisolfi, Ph.D.
Laura Ghisolfi, Ph.D., is a Senior Scientist at Accent Therapeutics, Inc., where she focuses on breast cancer metabolic properties and oversees research projects. She has a background in pharmacology and has contributed to significant findings in cancer research, including the identification of the antiporter xCT as a target of the PI3K/AKT signaling pathway.
Work at Accent Therapeutics
Laura Ghisolfi, Ph.D. serves as a Senior Scientist at Accent Therapeutics, Inc. since 2020. In this role, she oversees daily operations and manages research projects within Toker's Lab. Her work primarily focuses on the metabolic properties of breast cancer. Ghisolfi has developed novel protocols for isolating the xC- complex, which are utilized in biochemical assays. Her contributions are integral to advancing the understanding of cancer biology and therapeutic targets.
Collaboration with HMS Center for Glycoscience
Ghisolfi collaborates with the HMS Center for Glycoscience to study N-Glycosylation. This collaboration enhances her research capabilities and contributes to the understanding of glycosylation processes in cancer. The insights gained from this partnership aim to inform potential therapeutic strategies.
Previous Experience at Beth Israel Deaconess Medical Center
Before joining Accent Therapeutics, Ghisolfi worked at Beth Israel Deaconess Medical Center from 2009 to 2020 as a Research Scientist and Lab Manager. During her 11 years in the Greater Boston Area, she managed laboratory operations and contributed to various research initiatives, enhancing her expertise in cancer research.
Research Fellowship at Brigham and Women's Hospital
Ghisolfi completed a research fellowship at Brigham and Women's Hospital from 2008 to 2009. This year-long experience allowed her to further develop her research skills and knowledge in the field of biomedical science, laying the groundwork for her subsequent career in cancer research.
Education and Expertise in Pharmacology
Laura Ghisolfi earned her Ph.D. in Pharmacology from Università degli Studi di Milano, where she studied from 2005 to 2008. Her academic background provides a strong foundation for her research in cancer biology and metabolic processes, enabling her to contribute effectively to her current and previous roles.